Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.57 |
| ▸ | NR3C1 | P04150 | 14/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13869170 | 0.83 | KEAP1 (0.65) | KEAP1NFE2L2NR3C1PGRNR3C2 | |
| SCHEMBL21931626 | 0.79 | KEAP1 (0.59) | KEAP1NFE2L2NR3C1PGRNR3C2 | |
| SCHEMBL5203351 | 0.76 | KEAP1 (0.56) | KEAP1NFE2L2NR3C1PGRNR3C2 | |
| SCHEMBL15108064 | 0.73 | KEAP1 (1.00) | KEAP1NFE2L2NR3C1PGRNR3C2 | |
| SCHEMBL3364100 | 0.71 | ESR1 (0.41) | KEAP1NFE2L2NR3C1PGRNR3C2 | |
| SCHEMBL13263824 | 0.71 | GABRA1 (0.43) | — | |
| SCHEMBL14340526 | 0.71 | KEAP1 (0.49) | KEAP1NFE2L2NR3C1PGRNR3C2 | |
| SCHEMBL3962709 | 0.70 | KEAP1 (0.67) | KEAP1NFE2L2NR3C1PGRNR3C2 | |
| SCHEMBL5965425 | 0.70 | KEAP1 (0.67) | KEAP1NFE2L2NR3C1PGRNR3C2 | |
| SCHEMBL1335286 | 0.70 | KEAP1 (0.67) | KEAP1NFE2L2NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0887346-B1 | N-Phenyl-alkylsulfonamide derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists | HOFFMANN LA ROCHE (CH) | 2007-12-12 | — | — | EP | disclosed |
| US-6057349-A | ALPHA.SUB.1A/1L AGONISTS USED IN THE TREATMENT OF VARIOUS DISEASE STATES SUCH AS URINARY INCONTINENCE, NASAL CONGESTION, PRIAPISM, DEPRESSION, ANXIETY, DEMENTIA, SENILITY, ALZHEIMER'S, DEFICIENCIES IN ATTENTIVENESS AND COGNITION, AND | F. HOFFMAN LA ROCHE AG (CH) | 2000-05-02 | — | — | US | disclosed |
| US-5952362-A | INHIBITOR OF GLYCOGEN PHOSPHORYLASE ENZYMETIC ACTIVITY AND GLUCOSE ACITIVITY | SYNTEX (U.S.A) INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0887346-A2 | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-30 | — | — | EP | disclosed |